



Annual Review

2015-2016

Contents

Chairman’s Report	3
EURADIA’s Mission	4
What is EURADIA?	4
A Brief History of EURADIA	4
How EURADIA Works	5
EURADIA Priorities	5
DIAMAP 2020: Road Map for Diabetes Research in Europe	6
DIAMAP 2020: Progress during 2016	7
EURADIA Summer 2016 Research Meeting	8
High-level advocacy for Diabetes Research	10
ECD and EUDWG Meetings	11
European Networking Projects	13
Communications	15
Communications: Conference Participation and Exhibitions	16
Governance: Executive Committee and Secretariat	17
EURADIA Members	(back cover)

Chairman's Report



This has been an eventful and busy year for EURADIA. Updating the DIAMAP project is central to EURADIA's mission and is the tool that generates the material essential for a rational diabetes advocacy strategy targeting support for diabetes research at European and national level. We are extremely fortunate that Professor Chantal Mathieu from KU Leuven, Belgium is chairing this initiative; it is her skill and enthusiasm that has ensured progress during the past year. She has overseen the impact survey, which provided a basis for the update. The survey showed that the original DIAMAP is still current and useful, and has led to the development of a new interactive website.

Diabetes researchers and other stakeholders will no doubt be contacted about DIAMAP 2020, whether to add information to the database, or to participate in an expert group – please do take part in this useful initiative if you can!

Our first EURADIA summer meeting in July was warmly received. We held this event for a multi-stakeholder audience in Brussels, Belgium. In the following pages you can read the report and see photographs from the day – we wish to thank the participating speakers for their excellent contributions, we hope that they found the event useful and enjoyable. It is our great hope that more such events can be organised in the future and can generate a discussion about how different stakeholders can contribute to diabetes research in Europe.

European diabetes research was profiled during the EU Diabetes Working Group event (organised by the European Coalition for Diabetes) in the European Parliament, Strasbourg, France in February. During the event the Commissioner for Research and Innovation, Carlos Moedas, indicated his commitment to diabetes research and we hope to keep him updated on this through our activities.

Finally, we hope to see you and to hear your views at the EURADIA stand in the Association Village, during the EASD Meeting in Munich, Germany.

Michael Stumvoll

Professor of Medicine, Leipzig University, Germany, August 2016

EURADIA's Mission

As a unique alliance of non-governmental organisations (NGOs) and healthcare companies, EURADIA's mission is to improve the lives of people affected by diabetes both now and in the future, through advocacy of diabetes research in Europe at the highest political and societal levels of influence, by improving coordination of European Diabetes Research and by shaping the allocation of resources for such research through increased awareness.

What is EURADIA?

Who we are: EURADIA is an alliance of NGOs and healthcare companies working for diabetes research. The NGOs include European academic and clinical researchers, healthcare professionals and patient groups.

What we do: We provide a platform for all those undertaking research to work together to benefit the wellbeing of people with diabetes, **through advocacy for increased funding and improved coordination of diabetes research in Europe.**

We carry out research to provide information and other tools to support the translation of diabetes research findings into policy.

A Brief History of EURADIA

EURADIA was informally established in 2003 as the European Research Area in Diabetes. It began as a collaboration between NGOs and healthcare companies concerned that diabetes was properly represented by the European Commission in its Framework Research Programmes. This successful collaboration was formalised legally in 2007.

EURADIA has grown over the years to take on advocacy activity at the European level together with other European diabetes organisations. We also work in partnership with scientific projects to enable the translation of research results into policy to benefit people with diabetes.

EURADIA, as of September 2016, is in the process of transferring all its activity to the UK where it is now registered as a charity.

How EURADIA Works

EURADIA is funded entirely by its multi-stakeholder membership, which comprises (at the time of this report) seven non-profit organisations with interest in the field of diabetes research at a European level and five leading healthcare companies with European diabetes research and development activity. Membership fees are Euro 20,000 for industry and Euro 3,000 for NGOs, annually. Membership fees fund all EURADIA activity and EURADIA only undertakes activities that are funded by its entire membership.

The Executive Committee is representative of EURADIA's multi-stakeholder membership while the Chair must always be a representative from one of the non-commercial organisations.

The Secretariat comprises a small team working under the direction of a full-time Executive Director.

EURADIA holds two meetings a year: an Annual General Meeting during which strategic decisions are made, and a second meeting usually held during the EASD. EURADIA also organises external events for diabetes stakeholders and participates in events together with other like-minded organisations.

EURADIA Priorities

1. DIAMAP 2020: Road Map for Diabetes Research in Europe: review the current status of diabetes research and funding in Europe by updating and extending the DIAMAP database and expert road maps and developing an interactive website as a data collection/reporting tool.

2. High-level advocacy

- Ensure that diabetes research is well placed under Horizon 2020
- Follow up the *European Parliament Resolution for the EU Diabetes Epidemic*

3. Stakeholder engagement: harness support from the wider diabetes community

4. Networking projects: provide service to the diabetes research community by assisting the translation of research into clinical practice and policy

5. Communications: promote awareness of the importance of diabetes research.


DIAMAP 2020: Road Map for Diabetes Research in Europe

Priority for EURADIA: Update and extend the DIAMAP Road Map. Review the current status of diabetes research and funding in Europe by updating and extending the DIAMAP database and expert road maps.

The DIAMAP Road Map for Diabetes Research in Europe has the mission *to undertake a wide survey of the current European diabetes research landscape, from which expert opinion can identify gaps and highlight strengths, to guide a Road Map strategy for diabetes research in Europe.*

How the original DIAMAP Road Map Report was used

- By the European Commission and other funding organisations when drawing up calls for research funding applications
- As a reference point for researchers preparing grant applications



- In advocacy with the institutions at European and national level. The focus on research gaps and opportunities in the DIAMAP Road Map Report provides a rationale for policy-making to support future research and resource planning, and for translation of research results into policy and innovation in therapies and care delivery.
- As a template for other organisations to guide surveys and road mapping initiatives

DIAMAP 2020 will map the status of diabetes research in Europe; we will:

- Consult with stakeholders throughout 2016 and 2017
- Develop a flexible and interactive website that will present information about progress along the maps and updated databases
- Complete the survey of diabetes funding organisations and research activity and update the original DIAMAP databases
- Evaluate progress against the original DIAMAP research road map

WWW.DIAMAP.EU

DIAMAP 2020: progress during 2016



- The DIAMAP project update is being led by **Chantal Mathieu, Professor of Clinical and Experimental Endocrinology at KU Leuven, Belgium** (pictured left).
 - A DIAMAP Advisory Committee is established.
 - An updated DIAMAP funding questionnaire was circulated to European Commission National Contact Points and funding organisation respondents to the original DIAMAP project to collect information on funding and infrastructure support for diabetes research across Europe.
-
- An impact survey on the original DIAMAP project was undertaken by Ms Natalie van den Briel, a project manager working from KU Leuven.
 - Through an online survey, stakeholders from across the diabetes research community (researchers, policy makers, health professionals, funding agencies) were asked for their feedback regarding DIAMAP 1 and their expectations for DIAMAP 2020. Announcements were also made in the EASD electronic newsletter and on the Facebook page and other social media, along with publicity through EURADIA members' websites and contacts. A pop-up invitation and web link were incorporated on the DIAMAP website.
 - **Review of DIAMAP 1 road maps:** The expert groups who developed and drafted the original road maps were asked to review the report and road maps and to evaluate any progress made and where we are today. **The outcome was that much of the original work is still current and therefore still worthy of publicity and dissemination.**

DIAMAP 2020: next steps

- **Interactive website:** The main focus of the updating of DIAMAP is dissemination and bringing the report to the attention of key stakeholders. For this reason, an interactive website is being created whereby the existing maps can be presented and used as a dynamic tool by researchers. The new website will be launched in 2016.

WWW.DIAMAP.EU

EURADIA Summer 2016 Meeting

Sustainable Innovation in Diabetes Research: How Europe can Rise to the Challenge. 13 July 2016, Brussels, Belgium

The EURADIA Summer Meeting engaged research funding organisations, policy makers, industry, people with diabetes, scientists and clinicians in considering the unmet challenges in diabetes research and the ways in which they can be addressed. The programme consisted of world-renowned experts, people with diabetes, and European policy makers. A lively dialogue between speakers and participants was elegantly chaired by **Dr Carlo Acerini** (Cambridge, UK); **Dr Olivier Arnaud** (Juvenile Diabetes Research Foundation, France); **Professor Cliff Bailey** (Aston, UK); and **Professor Chantal Mathieu** (Leuven, Belgium).



Speakers included **Mr Johan Keurentjes** (Juvenile Diabetes Research Foundation, The Netherlands) who talked about his experience of living with type 1 diabetes. **Professor Decio Eizirik** (Brussels, Belgium) talked about preservation of beta cells. **Professor Hans De Vries** (Amsterdam, The Netherlands) spoke about control of blood glucose and types of

delivery systems. Immunotherapy and vaccination was addressed by **Professor Anette-Gabriele Ziegler** (München, Germany). **Mr Damjan Damjanović** (International Diabetes Federation Europe, Belgrade, Serbia) talked about type 2 diabetes and setting up a diabetes support organization. **Professor Cliff Bailey** (Aston, UK) then talked about potential new diabetes therapies.

The perspectives of the paediatric diabetes community were presented by **Dr Carlo Acerini** (Cambridge, UK). Then **Professor Hans-Peter Hammes** (Mannheim, Germany) spoke on research pipelines in retinopathy.

A lively discussion then touched on issues including: the possible need for diabetes to be re-classified, as the complications start before awareness of symptoms; partnerships between patients and researchers to design better research; the need for researchers to translate their work into accessible language; legal and ethical frameworks for research that uses new technologies; the need for improved biomarkers and phenotyping for more effective clinical trials. The final message was that Europe should be encouraged by both the quantity and quality of its diabetes research output.

During the afternoon, sessions focussed on institutions and organisations that support European diabetes research. **Dr Karim Berkouk** from DG Research and Innovation, European Commission (Brussels, Belgium) gave an overview of EU

funding. **Professor Norbert Stefan** (Tübingen, Germany) reviewed the German Diabetes Centers: A model for translational diabetes research.

Professor Markus Stoffel (Zurich, Switzerland) presented the EASD/EFSD and its mission, scope and funding instruments; including training programmes and courses. **Professor Nick Wareham** (Cambridge, UK) spoke about the need for data that is accessible, and can be shared and utilised in a scalable, sustainable way to allow comparing of data between populations as well as within populations.

A subject of interest to the membership of EURADIA was Academia-Industry partnerships: lessons learned from the Innovative Medicines Initiative (IMI) from **Professor Michel Goldman** (Brussels, Belgium). This was followed by a talk on collaborative European projects in diabetes from **Professor Chantal Mathieu** (Leuven, Belgium). Finally, **Mrs Heidi Janssen** (European Medicines Agency, London, UK) talked about the regulatory framework for new medicines.

A final discussion session was led by **Dr Olivier Arnaud** (JDRF, France) that covered the changing focus of collaborative European research: more personalised medicine; proof of concept studies for new therapies; proposals for better equipped clinical trials; and implementation research is increasing. When asked, Dr Berkouk said that most projects are funded for 4-5 years, but the upper limit is in fact 10 years.

It was emphasised again that patients were essential partners in research (an example being JDRF); however, new domains such as health economics and other new areas need to be included to address the problem of researchers working in 'silos'.

To summarise, **Professor Mathieu** reminded participants that research was not only the domain of researchers, but that everyone should be involved: from patients who could advise with ideas, to industry, policy makers and health professionals, who could all contribute in different ways.

A full report on the meeting can be obtained from the EURADIA website.



High-level Advocacy for Diabetes Research

Priority for EURADIA: Work within the European Coalition for Diabetes (ECD) and follow up the 2012 *European Parliament Resolution for the EU Diabetes Epidemic*



The European Coalition for Diabetes (ECD) was created by informal agreement between the Alliance for European Diabetes Research

(EURADIA), the Foundation of European Nurses in Diabetes (FEND), the International Diabetes Federation European Region (IDF Europe), and Primary Care Diabetes Europe (PCDE), who came together to coordinate EU policy action on combined objectives.

European Diabetes Working Group (EUDWG)

The EU Diabetes Working Group (EUDWG) is a group of cross-party, cross-national MEPs with particular interest in diabetes. The group is co-chaired by three MEPs with significant political profiles. The co-chairs are strongly committed to the objectives of the EUDWG. They represent in the European Parliament the best interests of all people with diabetes in Europe and provide dedicated support and advice to the diabetes community in driving policy change. The EUDWG is chaired, on a rotational basis, by one of three MEP co-chairs:



Therese Comodini Cachia
Malta
Group of the European People's Party



Marisa Matias
Portugal
Confederal Group of the European United Left - Nordic Green Left



Christel Schaldemose
Denmark
Group of the Progressive Alliance of Socialists and Democrats

WWW.ECDIABETES.EU

European Coalition for Diabetes (ECD) and European Diabetes Working Group (EUDWG) Meetings

Diabetes: The Unmet Needs. Key Priorities for European Diabetes Research. 3 February 2016, European Parliament, Strasbourg, France



Diabetes research was the focus of the EUDWG meeting (organised by ECD) in the European Parliament, Strasbourg, France. The principle aim of the EUDWG is to improve both prevention of diabetes, as well as the health and quality of life of European citizens living with diabetes, through EU policy. Within the European Parliament the aim is to

increase awareness of the disease in order to push for political actions on prevention and to improve early detection and therapy.

The meeting emphasised that in order for the EU to be a leader in prevention and treatment more investment in research is needed. The keynote speakers were **Commissioner for Research and Innovation Carlos Moedas** (pictured above), who was very appreciative of the work of the EUDWG, and **Professor Stefano del Prato** (Pisa, Italy) and Chair of the European Foundation for the Study of Diabetes (EFSD). The meeting included presentations and interventions from the host MEPs, the ECD co-chairs and a number of MEPs.



From left to right: Christel Schaldemose MEP, Prof Michael Stumvoll EURADIA Chair, Commissioner for Research and Innovation Carlos Moedas, Mr Chris Delicata ECD Chair

Commissioner Moedas noted that *“A great deal of research is still needed as diabetes continues to increase worldwide”*. The Commissioner mentioned that the EU wants to have a greater impact on diabetes through international research initiatives such as the Global Alliance for Chronic Diseases (GACD), to understand better *“the link between socio-economic influences and higher risks of diabetes, so that we can develop more holistic approaches to diabetes prevention, and so*

that personalised medicine and digital health technologies are made more effective by sound political decisions and awareness-raising campaigns”.

Commissioner Moedas congratulated the EUDWG for its efforts in the fight against the “diabetes space” as coined by **Professor Stumvoll**. He continued, “The achievements of this group ... are both very impressive and increasingly important”. The Commission, within the Horizon 2020 programme, will continue to support diabetes research and innovation. The Commissioner said that the presentations and discussions heard at the meeting were motivating and that he hoped that more could be achieved through communication with other stakeholders. He encouraged participants to get more people involved and that next year he would come back to discuss what had changed for people in the “diabetes space”.

Meeting between ECD Co-Chairs and Commissioner for Health and Food Safety Vytenis Andriukaitis. 12 July 2016, Brussels, Belgium

The meeting, which took place at the European Commission, began with a presentation by **ECD Chair Mr Chris Delicata** outlining the background to the ECD, current activity and achievements. The ECD publication, *Diabetes in Europe: The Policy Puzzle* was presented, highlighting the urgent need for more sustained and coordinated action to improve the implementation and evaluation of policies to act on diabetes. Fruitful discussions then considered possible approaches to the EU diabetes epidemic and how the ECD can help European institutions to follow up on the many declarations and resolutions that have addressed the issue.



From left to right: Anne Felton FEND President, Chris Delicata ECD Chair, Vytenis Andriukaitis Commissioner for Health and Food Safety, Xavier Cos PCDE Vice Chair, Sarah Hills EURADIA Executive Director

European Networking Projects

Priority for EURADIA: provide service to the diabetes research community by assisting the translation of research into clinical practice and policy

FP7-funded InterConnect: Global Initiative on Gene-Environment Interaction on Diabetes/Obesity risk. Grant number 602068



The FP7-funded InterConnect Initiative was funded by the EU in order to establish a global initiative to study gene-environment interaction on diabetes and obesity. Led by Coordinator **Professor Nick Wareham** (Cambridge, UK) (*pictured below*), the initiative aims to enable a new way of making use of existing data from individual studies around the world to enhance our ability to investigate why risk varies significantly between different populations. EURADIA is a partner in the Initiative and is responsible for the Stakeholder and Funder Engagement, and the Dissemination work packages.

InterConnect Symposium 2015: Global Data for Diabetes and Obesity Research. 14 September 2015, Stockholm, Sweden

This event aimed to engage researchers in a new approach to optimising the use of existing data that is secure, scalable, and sustainable within a simple governance framework. The FP7-funded InterConnect project seeks to create the foundation to enable research to move from explaining differences in the risk of diabetes and obesity *within* populations



to being able to explain differences in risk *between* populations. The meeting addressed how cross-cohort analyses are being enabled by an online study registry to enhance data discovery, optimising data for re-use via harmonisation and new toolkits, and by creating a network for federated meta-analysis where data stays at source and the analysis comes to the data. EURADIA is currently coordinating a second InterConnect Symposium to be held in Munich, Germany (pre-EASD) on Monday 12 September 2016.

WWW.INTERCONNECT-DIABETES.EU

European Networking Projects

Other initiatives with EURADIA involvement:



CHRODIS: Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle is a Joint Action

funded under the third EU Health Programme 2014-2020. EURADIA is involved through membership of the ECD, which participates through Work Package 7.

WWW.CHRODIS.EU



DALI: FP7-Funded DALI Diabetes and Pregnancy Vitamin D and Lifestyle Intervention for Gestational Diabetes Mellitus Prevention EURADIA was invited to

organise the final conference on 10 December 2015 in Brussels for the FP7-funded project: DALI Diabetes and Pregnancy Vitamin D and Lifestyle Intervention for Gestational Diabetes Mellitus Prevention.

WWW.DALI-PROJECT.EU

From left to right: Christel Schaldemose MEP and Therese Comodini Cachia MEP with Carlos Moedas Commissioner for Research and Innovation at the EUDWG Meeting 'Diabetes: The Unmet Needs. Key Priorities for European Diabetes Research', European Parliament, Strasbourg.



Communications

Priority for EURADIA: promote and raise awareness of the importance of diabetes research and the place of EURADIA within a wider European audience

- **EURADIA Newsletter:** circulated electronically to over 900 stakeholders. Newsletters are also available via the EURADIA website.
- **EURADIA Funding Bulletin:** bi-annual bulletin for diabetes researchers and other stakeholders, detailing the latest information on grants and funding around Europe.
- **EURADIA website:** WWW.EURADIA.ORG and the DIAMAP website WWW.DIAMAP.EU have been reviewed and updated. Both sites are being relaunched in 2016.



EURADIA slide set. A slide set has been developed giving an overview of our activities which is available on application to the Secretariat.

Conference participation. EURADIA exhibits at major European conferences across biomedical, health, and policy sectors.

EURADIA database. The contact list of EURADIA has grown steadily over the years since the DIAMAP project, and is now compiled into a bespoke relational database. Much EURADIA activity involves networking, disseminating and communicating with stakeholders, for the DIAMAP project, and for other projects. Currently it includes over a thousand organisations (mainly NGOs, government departments and agencies, industry, journalists and politicians, university research groups). **Please let us know if you would like to be added to this list.**

WWW.EURADIA.ORG

Communications: Conferences and Exhibitions

- EURADIA Research Meeting *Sustainable Innovation in Diabetes Research: How Europe can Rise to the Challenge*. 13 July 2016, Brussels, Belgium
- InterConnect FP7 Project, Consortium Meeting. 4 April 2016, Cambridge, UK
- European Union Diabetes Working Group Meeting, *Diabetes: The Unmet Needs. Key Priorities for European Diabetes Research*. 3 February 2016, European Parliament, Strasbourg, France
- InterConnect FP7 Project, Consortium Meeting. 27 November 2015, Amsterdam, Netherlands
- CHRODIS: *Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle*. 21 October 2015, Ljubljana, Slovenia
- European Association for the Study of Diabetes (EASD) Annual Meeting. 14-18 September 2015, Stockholm, Sweden
- InterConnect FP7 Project Symposium. 14 September 2015, Stockholm, Sweden
- Foundation of European Nurses in Diabetes (FEND) Annual Conference. 10-11 September 2015, Stockholm, Sweden
- IMI/JDRF workshop *Type 1 Diabetes Research: Taking Stock and Maximising Collaboration*. 23 June 2015, Brussels, Belgium
- European Union Diabetes Working Group Meeting, *Diabetes in Europe*. 5 May 2015, European Parliament Brussels, Belgium
- InterConnect FP7 Project, Consortium Meeting. 22 February 2015, Amsterdam, Netherlands
- European Forum for Good Clinical Practice Annual Meeting *How do we Improve Health without Betraying Confidentiality within Current and Upcoming EU Regulations?* 27 January 2015, Brussels, Belgium



Participants at the EURADIA Summer Research Meeting 'Sustainable Innovation in Diabetes Research: How Europe can Rise to the Challenge', Brussels, Belgium

Governance: Executive Committee and Secretariat

EURADIA e.V. Executive Committee

Chairman: **Michael Stumvoll**, Leipzig, Germany

Vice Chair: **Laurent Vaur**, Paris, France

Treasurer: **Philip Ambery**, London, UK

Committee Members: **Carlo Acerini**, Cambridge, UK

Olivier Arnaud, Paris, France

Honorary Auditor: **Chris Delicata**, St Julian's, Malta

Honorary Chairman: **Philippe Halban**, Geneva, Switzerland

EURADIA UK Trustees **Philippe Halban**, Geneva, Switzerland

Anne-Marie Felton, London UK

Secretariat:

Executive Director: **Sarah Hills**, Horsham, UK

Administrative support: **Silke Fritsch**, Leipzig, Germany

External support: **Anna Currado**, Freelance, Horsham, UK

Hilary Humphrey, SEOFON Business Services, Horsham, UK

Postal address:

Milnwood House, 13 North Parade,
Horsham, West Sussex, RH12 2BT, UK

Tel. 0044 (0)1403 276363

SECRETARIAT@EURADIA.ORG

WWW.EURADIA.ORG

EURADIA e.V., Registered at the County Court Düsseldorf, Germany, registry no. VR 9885

EURADIA Registered in England and Wales as a company limited by guarantee, registry no. 8608154 and as registered charity number 1154726.

EURADIA Members

(as of August 2016)

European Association for the Study of Diabetes (EASD)

European Society for Paediatric Endocrinology (ESPE)

Foundation of European Nurses in Diabetes (FEND)

German Center for Diabetes Research (DZD)

International Diabetes Federation European Region (IDF Europe)

Juvenile Diabetes Research Foundation International (JDRF)

Primary Care Diabetes Europe (PCD Europe)

Astra Zeneca

Boehringer Ingelheim

Eli Lilly and Company

Novo Nordisk

Sanofi
